Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California 94158, United States.
California Quantitative Biosciences Institute (QBI) at UCSF, San Francisco, California 94158, United States.
ACS Synth Biol. 2023 Jul 21;12(7):1924-1934. doi: 10.1021/acssynbio.3c00080. Epub 2023 Jun 14.
Protein-based switches that respond to different inputs to regulate cellular outputs, such as gene expression, are central to synthetic biology. For increased controllability, multi-input switches that integrate several cooperating and competing signals for the regulation of a shared output are of particular interest. The nuclear hormone receptor (NHR) superfamily offers promising starting points for engineering multi-input-controlled responses to clinically approved drugs. Starting from the VgEcR/RXR pair, we demonstrate that novel (multi)drug regulation can be achieved by exchange of the ecdysone receptor (EcR) ligand binding domain (LBD) for other human NHR-derived LBDs. For responses activated to saturation by an agonist for the first LBD, we show that outputs can be boosted by an agonist targeting the second LBD. In combination with an antagonist, output levels are tunable by up to three simultaneously present small-molecule drugs. Such high-level control validates NHRs as a versatile, engineerable platform for programming multidrug-controlled responses.
基于蛋白质的开关可以响应不同的输入来调节细胞输出,如基因表达,这是合成生物学的核心。为了提高可控性,人们对多输入开关特别感兴趣,这种开关可以整合几个协同和竞争的信号,以调节共享的输出。核激素受体(NHR)超家族为工程化多输入控制对临床批准药物的反应提供了有前途的起点。从 VgEcR/RXR 对开始,我们证明通过交换蜕皮激素受体(EcR)配体结合域(LBD),可以用其他人类 NHR 衍生的 LBD 来实现新的(多)药物调节。对于第一个 LBD 的激动剂激活到饱和的反应,我们证明可以通过针对第二个 LBD 的激动剂来增强输出。与拮抗剂结合,输出水平可以通过同时存在的三种小分子药物进行调节。这种高水平的控制验证了 NHR 作为一种多功能、可工程化的平台,可用于编程多药物控制的反应。